BioCryst Net Income From Continuing Ops from 2010 to 2026
| BCRX Stock | USD 6.76 0.04 0.59% |
Net Loss | First Reported 2000-03-31 | Previous Quarter 5.1 M | Current Value 12.9 M | Quarterly Volatility 20.4 M |
Check BioCryst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioCryst Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 979.9 K, Interest Expense of 119 M or Selling General Administrative of 304.9 M, as well as many indicators such as Price To Sales Ratio of 3.77, Dividend Yield of 0.0 or Days Sales Outstanding of 69.96. BioCryst financial statements analysis is a perfect complement when working with BioCryst Pharmaceuticals Valuation or Volatility modules.
BioCryst | Net Income From Continuing Ops | Build AI portfolio with BioCryst Stock |
The evolution of Net Income From Continuing Ops for BioCryst Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how BioCryst Pharmaceuticals compares to historical norms and industry peers.
Latest BioCryst Pharmaceuticals' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of BioCryst Pharmaceuticals over the last few years. It is BioCryst Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioCryst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
BioCryst Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (100,882,144) | |
| Coefficient Of Variation | (69.38) | |
| Mean Deviation | 54,660,957 | |
| Median | (79,992,900) | |
| Standard Deviation | 69,996,705 | |
| Sample Variance | 4899.5T | |
| Range | 217M | |
| R-Value | (0.58) | |
| Mean Square Error | 3494.1T | |
| R-Squared | 0.33 | |
| Significance | 0.02 | |
| Slope | (7,979,931) | |
| Total Sum of Squares | 78392.6T |
BioCryst Net Income From Continuing Ops History
About BioCryst Pharmaceuticals Financial Statements
BioCryst Pharmaceuticals investors use historical fundamental indicators, such as BioCryst Pharmaceuticals' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioCryst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -80 M | -84 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.